Polaris Cancer Drug Candidate Enters FDA Substantive Review
MT Newswires Live
Aug 19, 2025
Polaris Group (TPE:6550) said the U.S. Food and Drug Administration (FDA) has accepted its biologics license application (BLA) for pegargiminase (ADI-PEG 20), moving the cancer therapy into substantive review, according to a Tuesday filing on the Vietnam Stock Exchange.
The submission covers the use of ADI-PEG 20 for patients with malignant pleural mesothelioma with non-epithelioid histology, in combination with a platinum agent and pemetrexed.
The final portion of the rolling BLA was filed on June 9. Polaris held an orientation meeting with nearly 120 FDA reviewers in early August to address questions on the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.